ABVC BioPharma provides Vitargus update on Phase II SIV

ABVC BioPharma announced that Vitargus Phase II Site Initiation Visit, SIV, at Ramathibodi Hospital, Faculty of Medicine, Mahidol University, TH001, in Thailand was successfully conducted on March 22, 2023. The SIV was an organized meeting to discuss the Phase II study protocol with the principal investigator, Duangnate Rojanaporn, M.D. and begin training clinical personnel. Vitargus Phase II study with the protocol "A Prospective Multi-Site Open-Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of ABV-1701 Ocular Endotamponade (OE)" is to demonstrate safety and effectiveness of Vitargus in patients with Retinal Detachment compared to the commonly used Sulphur Hexafluoride Gas OE. The Phase II study screening and enrollment has been initiated and will aim to enroll at least 40 patients across all four sites in Australia and Thailand.